Hints and tips:
...from our discovery organization has grown, and new medicines from both our own and external research have entered late stage development, including those from recent licensing transactions,” said David Brennan...
...Earlier this month, David Brennan, AstraZeneca’s incoming chief executive, said his focus would be on strengthening the pipeline, by licencing in late-stage products....
International Edition